The Chemours Company (NYSE:CC) Given Average Recommendation of "Hold" by Analysts

The Chemours Company (NYSE:CC - Get Free Report) has been given an average recommendation of "Hold" by the eight research firms that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $24.88.

Several research firms have weighed in on CC. The Goldman Sachs Group decreased their price target on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating for the company in a research note on Tuesday, September 3rd. Morgan Stanley dropped their price objective on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 5th. JPMorgan Chase & Co. dropped their price objective on shares of Chemours from $25.00 to $18.00 and set a "neutral" rating on the stock in a report on Tuesday, August 6th. Barclays upped their price objective on shares of Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Finally, UBS Group dropped their price objective on shares of Chemours from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th.

Chemours Trading Down 1.6 %

NYSE CC traded down $0.35 during mid-day trading on Wednesday, reaching $21.28. 1,004,893 shares of the stock were exchanged, compared to its average volume of 1,566,413. Chemours has a one year low of $15.10 and a one year high of $32.70. The stock has a 50 day simple moving average of $19.81 and a 200-day simple moving average of $21.14. The stock has a market cap of $3.18 billion, a P/E ratio of 42.86 and a beta of 1.80. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter last year, the firm earned $0.64 earnings per share. Chemours's quarterly revenue was up .9% on a year-over-year basis. On average, analysts anticipate that Chemours will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 4.70%. The ex-dividend date is Friday, November 15th. Chemours's payout ratio is 200.00%.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Appian Way Asset Management LP purchased a new stake in Chemours in the 3rd quarter worth approximately $34,151,000. Vision One Management Partners LP bought a new position in shares of Chemours in the 3rd quarter worth $28,252,000. Marshall Wace LLP increased its holdings in shares of Chemours by 23.8% in the 2nd quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company's stock worth $158,213,000 after buying an additional 1,347,710 shares during the last quarter. Khrom Capital Management LLC increased its holdings in shares of Chemours by 54.6% in the 2nd quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company's stock worth $78,016,000 after buying an additional 1,220,967 shares during the last quarter. Finally, Scopia Capital Management LP bought a new position in shares of Chemours in the 3rd quarter worth $13,623,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.